Sequential dual-targeting biomimetic nanovesicles for bone marrow-specific delivery of bortezomib in multiple myeloma.

ABSTRACT:

Introduction

Inefficient bone marrow targeting remains a major barrier to improving clinical outcomes in multiple myeloma (MM). Although bortezomib (BTZ), a first-line proteasome inhibitor, exhibits potent antitumor activity, its short half-life, dose-limiting off-target toxicity, and pronounced neurotoxicity severely constrain therapeutic utility.

Methods

Here, we report the design of a sequentially dual-targeted biomimetic nanoplatform that integrates the high affinity of alendronate for hydroxyapatite in the bone matrix with the homotypic targeting capability of MM cell membranes, thereby enabling a hierarchical "bone-first, tumor-next" delivery paradigm. This two-stage navigation strategy allows the nanoparticles to anchor specifically within the bone microenvironment an

SUBMITTER: Lu C 

PROVIDER: S-EPMC12665660 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature